Toad venom to treat depression? RA Capital wagers $125M on latest psychedelic biotech
Can an inhaled version of the psychedelic known as ‘toad venom’ be used to treat tough-to-crack depression? For GH Research, that’s the $125 million question.
The Dublin-based biotech announced Monday it closed a Series B round to help advance its lead program, an inhalant called GH001, for psychiatric and neurological disorders. GH is beginning with treatment-resistant depression and has two as-yet-undisclosed indications on tap.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.